Skip to main content

Table 1 Clinical and Biological characteristics of patients with Neuroblastoma evaluated according to tumour ploidy status.

From: Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status

Case number

ploidy

Age

INSS stage

MYCN amplification

Disease Status

Survival Status

microarray analysis

validation analysis

  

<12m=0; >12m=1

1,2,3,4s=0; 4=1

     

1

near-3n

1

0

NA

NP

A

Y

Y

2

near-3n

1

0

NA

NP

A

Y

.

3

near-3n

1

0

NA

NP

A

Y

Y

4

near-3n

0

0

NA

NP

A

Y

.

5

near-3n

0

0

NA

NP

A

Y

Y

6

near-3n

0

0

NA

NP

A

Y

.

7

near-3n

0

0

NA

P

A

Y

.

8

near-3n

0

0

NA

P

A

Y

.

9

near-3n

0

0

NA

NP

A

Y

.

10

near-3n

0

0

NA

NP

A

Y

.

11

near-3n

1

0

NA

NP

A

Y

Y

12

near-3n

0

0

NA

NP

A

Y

.

13

near-3n

1

1

NA

P

D

Y

.

14

near-3n

1

0

NA

NP

A

Y

.

15

near-3n

0

0

NA

NP

A

Y

Y

16

near-3n

0

0

NA

NP

A

Y

.

17

near-3n

0

0

NA

P

A

Y

Y

18

near-3n

1

1

NA

P

D

Y

Y

19

near-3n

1

0

NA

NP

A

Y

.

20

near-3n

1

0

NA

NP

A

Y

Y

21

near-3n

0

0

NA

P

A

Y

.

22

near-3n

1

0

NA

P

D

Y

Y

23

near-3n

0

0

NA

NP

A

.

Y

24

near-3n

0

0

NA

NP

A

.

Y

25

near-3n

0

0

NA

NP

A

.

Y

26

near-3n

0

0

NA

NP

A

.

Y

27

near-3n

1

0

NA

NP

A

.

Y

28

near-3n

1

0

NA

NP

A

.

Y

29

near-3n

1

0

NA

NP

A

.

Y

30

near-3n

1

0

NA

NP

A

.

Y

31

near-3n

0

1

NA

NP

A

.

Y

32

near-3n

0

0

NA

NP

A

.

Y

33

near-3n

1

1

NA

P

A

.

Y

34

near-3n

0

0

NA

NP

A

.

Y

35

near-3n

0

0

NA

P

D

.

Y

36

near-3n

0

0

NA

NP

A

.

Y

37

near-3n

0

0

NA

NP

A

.

Y

38

near-2n

1

1

A

NP

A

Y

Y

39

near-2n

1

1

A

P

D

Y

Y

40

near-2n

1

0

NA

P

D

Y

.

41

near-2n

1

1

A

P

D

Y

Y

42

near-2n

1

1

A

P

A

Y

Y

43

near-2n

1

1

NA

NP

A

Y

Y

44

near-2n

1

1

NA

P

D

Y

.

45

near-2n

1

1

A

P

D

Y

.

46

near-2n

1

1

NA

NP

A

Y

.

47

near-2n

1

0

NA

P

D

Y

.

48

near-2n

1

0

NA

P

D

Y

.

49

near-2n

0

1

A

NP

A

Y

.

50

near-2n

0

0

NA

NP

A

Y

Y

51

near-2n

0

0

NA

P

A

Y

.

52

near-2n

1

1

A

P

D

Y

Y

53

near-2n

1

0

A

NP

A

Y

Y

54

near-2n

1

0

NA

NP

A

Y

.

55

near-2n

1

1

NA

P

D

Y

Y

56

near-2n

0

0

NA

P

A

Y

.

57

near-2n

0

0

NA

NP

A

Y

.

58

near-2n

1

1

NA

P

D

Y

.

59

near-2n

1

1

NA

P

D

Y

Y

60

near-2n

1

0

NA

P

D

Y

.

61

near-2n

0

0

NA

NP

A

.

Y

62

near-2n

1

1

NA

P

D

.

Y

63

near-2n

1

1

A

P

D

.

Y

64

near-2n

1

1

NA

NP

A

.

Y

65

near-2n

1

1

NA

P

D

.

Y

66

near-2n

0

0

A

NP

A

.

Y

67

near-2n

1

1

A

P

D

.

Y

68

near-2n

1

1

NA

P

A

.

Y

69

near-4n

1

0

NA

NP

A

Y

.

70

near-4n

0

1

A

P

D

Y

Y

71

near-4n

1

1

NA

NP

A

Y

Y

72

near-4n

0

1

NA

P

A

Y

.

73

near-4n

1

0

A

P

D

.

Y

74

near-4n

1

1

A

P

D

.

Y

  1. MYCN amplification status: NA = not amplified, A = amplified. Disease status: NP = no disease progression, P = disease progression. Survival status: A = alive, D = dead. Microarray and validation analyses: Y = cases analyzed.